David Lebowitz
Stock Analyst at Citigroup
(4.31)
# 331
Out of 5,172 analysts
119
Total ratings
59.77%
Success rate
13.35%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $70.99 | +18.33% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $61.70 | +36.14% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $30.90 | +55.34% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $12.02 | +66.39% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $221.43 | +30.97% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $90.78 | +13.46% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $32.33 | +17.54% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $33.38 | -34.09% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $68.54 | -2.25% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $41.27 | +35.69% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $12.84 | -22.12% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.29 | +16.28% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $65.30 | -31.09% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $88.51 | -23.17% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $441.16 | -13.41% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $54.13 | +77.35% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $5.02 | +139.04% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $312.17 | -47.46% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $22.21 | +75.60% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $24.23 | -13.33% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $7.63 | +5,207.99% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.04 | +360.53% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $70.99
Upside: +18.33%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $61.70
Upside: +36.14%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $30.90
Upside: +55.34%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $12.02
Upside: +66.39%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $221.43
Upside: +30.97%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $90.78
Upside: +13.46%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $32.33
Upside: +17.54%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $33.38
Upside: -34.09%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $68.54
Upside: -2.25%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $41.27
Upside: +35.69%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $12.84
Upside: -22.12%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.29
Upside: +16.28%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $65.30
Upside: -31.09%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $88.51
Upside: -23.17%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $441.16
Upside: -13.41%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $54.13
Upside: +77.35%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $5.02
Upside: +139.04%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $312.17
Upside: -47.46%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $22.21
Upside: +75.60%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $24.23
Upside: -13.33%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $7.63
Upside: +5,207.99%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.04
Upside: +360.53%